Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-arm phase II study of bevacizumab plus temozolomide in recurrent glioblastoma multiforme
2010-019051-21Phase 2Completed
- Sponsor
- Roche Farma, S.A.
- Start
- Mar 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and temozolomide in glioblastoma (GBM), sponsored by Roche Farma, S.A. Primary endpoint: Progression-free survival at 6 months. Started Mar 2010; status: completed.
02
Drugs
bevacizumabtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2010-019051-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019051-21.